The Danish Warfarin-Dialysis Study - Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 718 participants.

Also called NCT03862859

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 718 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03862859
  • EudraCT 2018-000484-86
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Denmark (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT03862859. Randomized; no masking; primary purpose prevention. Start 2019-10-09 (actual); primary completion 2027-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Danish Warfarin-Dialysis Study - Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis
Acronym
DANWARD
Condition
Atrial Fibrillation and Flutter
Condition
Stroke
Condition
Major Bleed
Condition
End-stage Renal Disease
Intervention (Drug)
Warfarin
Lead sponsor
Nicholas Carlson (class: other)
Collaborator
Danish Heart Foundation (class: other)

Record details

Record id
cardio:ct-nct03862859
Content hash
28f176a764ff5587c75bfea82e7457ab55d2f9cfaf5aaf83797340397fe39ed6